与分娩后出血相关的补充介导的血溶性尿素综合征:病例系列和个人参与者数据的系统审查
Anna Gurevich-Shapiro1,2,3, Sharon Orbach-Zinger3,4, Avi Leader3,5
1Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Research and practice in thrombosis and haemostasis
|December 24, 2024
概括
产后出血可以导致补充介导的血溶性尿素综合征 (CM-HUS),主要是在孕前或剖腹产后分娩的妇女中. 与单独的支持性护理相比,早期使用C5抑制剂和血交换的治疗显著改善了结局.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 产科 产科 产科 产科 产科
背景情况:
- 产后出血 (PPH) 是补充介导的血液溶解尿素综合征 (CM-HUS) 的潜在危险因素,以前被称为非典型的HUS.
- PPH在CM-HUS沉中的特定作用尚未被系统地研究.
- 了解这种关联对于产后期CM-HUS的及时诊断和管理至关重要.
研究的目的:
- 系统地检查产后出血在导致CM-HUS的作用.
- 描述PPH相关的CM-HUS的临床特征,预后和最佳管理策略.
主要方法:
- 从案例系列和报告中对个体参与者数据进行了系统审查.
- 包括来自作者机构的三个额外案件的数据.
- 搜索词集中在血栓式微血管病变,非典型的HUS,补充介导疾病,怀孕和产后出血.
主要成果:
- 这项研究包括48名来自文学和3名来自该机构的妇女,她们患有PPH相关的CM-HUS.
- 大多数患者在预产期出现,通常是剖腹产后,同时出现妊娠前或胎儿死亡.
- 与C5抑制剂和/或血交换治疗导致明显更好的结局 (87%的正常化) 与仅支持性护理相比 (18%的正常化).
结论:
- CM-HUS是产后出血后的一种罕见但严重的并发症,特别是在孕前或剖腹产后分娩的妇女身上.
- 及时使用C5抑制剂和/或血交换的治疗与PPH相关的CM-HUS.HUS中脏预后的改善有关.
- 仅仅是支持性护理效果较差,这凸显了针对性治疗的必要性.
关键词:
补充C5抑制剂可以补充.分割的方法 分割的方法急性脏损伤急性脏损伤是什么非典型的血液溶解尿素性尿性综合征.产后出血 产后出血是什么在产后的产后期.怀孕 怀孕 怀孕 怀孕 怀孕怀孕并发症 怀孕并发症血栓性微血管病变 - 血栓性微血管病变治疗结果 治疗结果更多相关视频
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
710
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
11.2K
相关概念视频
Rh Blood Group
1.2K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.2K
Introduction to Hemostasis
3.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
3.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
532
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
532
Disorders of Hemostasis
638
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
638
Humoral Immune Responses
69.7K
Overview
69.7K
Blood Transfusion and Agglutination
10.6K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.6K
